• 1
    The Seventh Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289:25602572.
  • 2
    Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002; 287:10031010.
  • 3
    Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998; 339:19571963.
  • 4
    Safar ME, Bouthier JA, Levenson JA, et al. Peripheral large arteries and the response to antihypertensive treatment. Hypertension. 1983;5(5 pt 2):III63III68.
  • 5
    O'Rourke MF. From theory into practice: arterial haemodynamics in clinical hypertension. J Hypertens. 2002; 20:19011915.
  • 6
    O'Rourke MF, Staessen JA, Vlachopoulos C et al. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens. 2002; 15:426444.
  • 7
    Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens. 2005;18 (1 Pt 2):3S10S.
  • 8
    London GM, Blacher J, Pannier B, et al. Arterial wave reflections and survival in end-stage renal failure. Hypertension. 2001; 38:434438.
  • 9
    Nurnberger J, Keflioglu-Scheiber A, Opazo Saez AM, et al. Augmentation index is associated with cardiovascular risk. J Hypertens. 2002; 20:24072414.
  • 10
    Morgan T, Lauri J, Bertram D, et al. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004; 17:118123.
  • 11
    Fye WB. T. Lauder Brunton and amyl nitrite: a Victorian vasodilator. Circulation. 1986; 74:222229.
  • 12
    Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981; 218:739749.
  • 13
    Safar ME. Reply: management of hypertension in the elderly. N Engl J Med. 1980;303:1234.
  • 14
    Duchier J, Iannascoli F, Safar M. Antihypertensive effect of sustained- release isosorbide dinitrate for isolated systolic systemic hypertension in the elderly. Am J Cardiol. 1987; 60:99102.
  • 15
    Stokes GS. Systolic hypertension in the elderly: pushing the frontiers of therapy-α suggested new approach. J Clin Hypertens (Greenwich). 2004; 6(4):192197.
  • 16
    Stokes GS, Ryan M, Brnabic A, et al. A controlled study of the effects of isosorbide mononitrate on arterial blood pressure and pulse wave form in systolic hypertension. J Hypertens. 1999;17(12 pt 1):17671773.
  • 17
    Stokes GS, Barin ES, Gilfillan KL. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension. 2003; 41:297301.
  • 18
    Nordlander R, Walter M. Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group. Eur Heart J. 1994; 15:108113.
  • 19
    Stokes GS, Bune AJ, Huon N, et al. Long-term effectiveness of extended-release nitrate for the treatment of systolic hypertension. Hypertension. 2005; 45:380384.